Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1991 1
1992 1
1993 3
1994 2
1995 3
1996 1
1997 2
1998 1
1999 6
2000 2
2001 2
2002 1
2004 1
2016 1
2020 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Outpatient vaginal cuff brachytherapy for endometrial cancer.
Petereit DG, Tannehill SP, Grosen EA, Hartenbach EM, Schink JC. Petereit DG, et al. Among authors: grosen ea. Int J Gynecol Cancer. 1999 Nov;9(6):456-462. doi: 10.1046/j.1525-1438.1999.99061.x. Int J Gynecol Cancer. 1999. PMID: 11240811
Hormone replacement therapy in breast cancer.
DiSaia PJ, Odicino F, Grosen EA, Cowan B, Pecorelli S, Wile AG. DiSaia PJ, et al. Among authors: grosen ea. Lancet. 1993 Nov 13;342(8881):1232. doi: 10.1016/0140-6736(93)92209-c. Lancet. 1993. PMID: 7901541 No abstract available.
Cytokine induction by 41.8 degrees C whole body hyperthermia.
Robins HI, Kutz M, Wiedemann GJ, Katschinski DM, Paul D, Grosen E, Tiggelaar CL, Spriggs D, Gillis W, d'Oleire F. Robins HI, et al. Among authors: grosen e. Cancer Lett. 1995 Nov 6;97(2):195-201. doi: 10.1016/0304-3835(95)03976-4. Cancer Lett. 1995. PMID: 7497463
A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia.
Robins HI, Katschinski DM, Longo W, Grosen E, Wilding G, Gillis W, Kraemer C, Tiggelaar CL, Rushing D, Stewart JA, Spriggs D, Love R, Arzoomanian RZ, Feierabend C, Alberti D, Morgan K, Simon K, d'Oleire F. Robins HI, et al. Among authors: grosen e. Cancer Chemother Pharmacol. 1999;43(5):409-14. doi: 10.1007/s002800050915. Cancer Chemother Pharmacol. 1999. PMID: 10100597
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL. Rocconi RP, et al. Among authors: grosen ea. Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7. Lancet Oncol. 2020. PMID: 33271095 Clinical Trial.
29 results